United States

KaloBios initiates phase II study with KB001-A in cystic fibrosis

Friday, January 11, 2013 12:10 PM

KaloBios Pharmaceuticals, a biopharmaceutical company based in San Francisco, Calif., has initiated dosing in a randomized, double-blind, placebo-controlled phase II clinical trial of KB001-A, the company's anti-PcrV Humaneered, PEGylated monoclonal antibody fragment. The study will investigate the safety and efficacy of intravenously administered KB001-A as a treatment for chronic Pseudomonas aeruginosa (Pa) infection in cystic fibrosis patients.

More... »

Saint Luke's Hospital unveils Neuroscience Institute

Friday, January 11, 2013 11:42 AM

Designed to serve as one of the preeminent neuroscience centers in the country, the Saint Luke's Neuroscience Institute (SLNI) tower officially opened January 9 at Saint Luke's Hospital. The new facility, specializing in streamlined care for neurological disorders, offers the Kansas City community and the entire region a dedicated neuroscience hospital, created to lead the way in research, medical advancements, patient outcomes, comfort and quality of care.

More... »

PAREXEL chairman and CEO Josef von Rickenbach elected 2013 ACRO chairman

Thursday, January 10, 2013 02:18 PM

PAREXEL International chairman and CEO, Josef von Rickenbach, has been named 2013 chairman of the Association of Clinical Research Organizations (ACRO).

More... »

Coronado appoints Weisman as CEO

Wednesday, January 9, 2013 12:08 PM

Coronado Biosciences, a Burlington, Mass.-based biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, has appointed Harlan F. Weisman, M.D., as its new chairman and CEO.

More... »

Exela Pharma Sciences to create 38 jobs

Wednesday, January 9, 2013 11:11 AM

Exela Pharma Sciences, a pharmaceutical manufacturer and subsidiary of Exela PharmSci, will expand its facility in Lenoir, N.C.

More... »

BIND, Amgen ink agreement for development of a kinase inhibitor nanomedicine

Wednesday, January 9, 2013 10:13 AM

BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, has entered into a global collaboration agreement with Amgen, a biotech based in Thousand Oaks, Calif., to develop and commercialize a kinase inhibitor nanomedicine for treating a range of solid tumors.

More... »

Kareus initiates phase I trial in Alzheimer's disease

Friday, January 4, 2013 02:51 PM

Kareus Therapeutics, a private biotechnology company focused on unmet treatment of age-related and chronic diseases, has initiated a phase I clinical study following the Investigational New Drug (IND) approval from the FDA for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.

More... »

Tim Mayleben named president and CEO of Esperion Therapeutics

Friday, January 4, 2013 01:56 PM

Esperion Therapeutics, a developer of small molecule therapies for the treatment of cardiometabolic disorders, has named Tim Mayleben as the new president and CEO of the company. Roger Newton, Ph.D., FAHA, who is the founder of Esperion and has been serving as its president and CEO, will become executive chairman and chief scientific officer.

More... »

Heffernan and Koch join Lilly’s autoimmune team

Friday, January 4, 2013 01:17 PM

Global pharmaceutical company Eli Lilly has appointed Michael P. Heffernan, M.D., a nationally recognized expert in complex medical dermatology, psoriasis and clinical trials, as a distinguished medical fellow of its autoimmune team. Alisa E. Koch, M.D., a rheumatologist who has won numerous academic awards for her extensive work in rheumatoid arthritis, also joined the team as senior medical fellow.

More... »

CRA receives silver Best in Biz Award for executive team of the year

Wednesday, January 2, 2013 04:01 PM

Clinical Research Advantage (CRA), a service provider based in Tempe, Ariz., received a national honor in this year’s Best in Biz Awards, the only independent business awards program judged by members of the press and industry analysts. CRA received the silver award for executive team of the year.

More... »